ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.474,97
0,10%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,0462
-0,57%
Bitcoin
107.877,78
4,62%
Brent Oil
79,035
-1,47%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Panacea Acquisition Corp (NUVB)

  7. Panacea Acquisition Corp (NUVB) Notícias

NUVB

Panacea Acquisition (NUVB)

Panacea Acquisition Corp
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:NUVB
DataHoraFonteTítuloCódigoCompanhia
06/01/202518:05Business WireNuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
06/01/202510:00Business WireNuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung CancerNYSE:NUVBPanacea Acquisition Corp
23/12/202410:00Business WireU.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung CancerNYSE:NUVBPanacea Acquisition Corp
20/12/202409:10PR Newswire (US)Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products AdministrationNYSE:NUVBPanacea Acquisition Corp
26/11/202410:00Business WireNuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNYSE:NUVBPanacea Acquisition Corp
13/11/202418:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
12/11/202418:05Business WireNuvation Bio to Present at the Jefferies London Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
06/11/202418:43Edgar (US Regulatory)Form 8-K - Current reportNYSE:NUVBPanacea Acquisition Corp
06/11/202418:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NUVBPanacea Acquisition Corp
06/11/202418:05Business WireNuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
09/10/202417:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
07/10/202417:05Business WireNuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial OfficerNYSE:NUVBPanacea Acquisition Corp
14/09/202404:05Business WirePositive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024NYSE:NUVBPanacea Acquisition Corp
09/09/202409:00Business WireNuvation Bio to Present at the Cantor Global Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
16/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:NUVBPanacea Acquisition Corp
15/08/202417:46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NYSE:NUVBPanacea Acquisition Corp
13/08/202417:02Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNYSE:NUVBPanacea Acquisition Corp
05/08/202417:58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:NUVBPanacea Acquisition Corp
05/08/202409:00Business WireNuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
30/07/202417:13Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNYSE:NUVBPanacea Acquisition Corp
30/07/202417:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:NUVBPanacea Acquisition Corp
23/07/202417:05Business WireNuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, TaletrectinibNYSE:NUVBPanacea Acquisition Corp
16/07/202410:03Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNYSE:NUVBPanacea Acquisition Corp
01/06/202409:10Business WireNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingNYSE:NUVBPanacea Acquisition Corp
29/05/202417:05Business WireNuvation Bio to Present at the Jefferies Global Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
24/05/202417:40Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNYSE:NUVBPanacea Acquisition Corp
14/05/202417:05Business WireNuvation Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
24/04/202411:01Business WireNuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNYSE:NUVBPanacea Acquisition Corp
10/04/202417:01Business WireNuvation Bio Completes Acquisition of AnHeart TherapeuticsNYSE:NUVBPanacea Acquisition Corp
28/03/202409:00Business WireNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial OfficerNYSE:NUVBPanacea Acquisition Corp
 Apresentando as notícias mais relevantes sobre:NYSE:NUVB

Seu Histórico Recente

TG
0EF
elf Beauty
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados